Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Antidepressant-binding sites in brain and platelets.

S Z Langer, A M Galzin, C R Lee

    Ciba Foundation Symposium
    |January 1, 1986
    PubMed
    Summary

    Reduced serotonin transporter binding sites in platelets may indicate depression. Researchers explored potential endogenous ligands, like 5-methoxytryptoline, that could influence these sites and play a role in depression pathogenesis.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Miliary fibromas in tuberous sclerosis complex.

    Journal of the European Academy of Dermatology and Venereology : JEADV·2021
    Same author

    Thyroid nodules in xeroderma pigmentosum patients: a feature of premature aging.

    Journal of endocrinological investigation·2020
    Same author

    Pharmacogenomics study of thiazide diuretics and QT interval in multi-ethnic populations: the cohorts for heart and aging research in genomic epidemiology.

    The pharmacogenomics journal·2017
    Same author

    The IGNITE Pharmacogenetics Working Group: An Opportunity for Building Evidence with Pharmacogenetic Implementation in a Real-World Setting.

    Clinical and translational science·2017
    Same author

    Robotic surgery for thyroid disease.

    Minerva chirurgica·2015
    Same author

    The anteroposterior axis of the tibia in Korean patients undergoing total knee replacement.

    The bone & joint journal·2014

    Area of Science:

    • Neuroscience
    • Biochemistry

    Background:

    • [3H]Imipramine and [3H]paroxetine bind to serotonin transporter sites in the brain and platelets.
    • Reduced maximum binding capacity (Bmax) of [3H]imipramine in platelets is observed in untreated depressed patients, suggesting potential as a biological marker for depression.

    Purpose of the Study:

    • To investigate the existence and role of an endogenous ligand that modulates the serotonin transporter via the [3H]imipramine-recognition site.
    • To explore the potential involvement of such an 'endocoid' in the pathogenesis of depression.

    Main Methods:

    • Radioligand binding assays using [3H]imipramine and [3H]paroxetine to label serotonin transporter sites.
    • Assessment of [3H]imipramine binding and [3H]serotonin uptake inhibition by 5-methoxytryptoline.

    Main Results:

    • The maximum binding capacity (Bmax) for [3H]imipramine in platelets is decreased in individuals with untreated depression.
    • 5-Methoxytryptoline demonstrated inhibitory effects on both [3H]imipramine binding and [3H]serotonin uptake at nanomolar concentrations.

    Conclusions:

    • A reduced platelet [3H]imipramine binding capacity may serve as a biological marker for depression.
    • While the physiological significance is uncertain, 5-methoxytryptoline or similar compounds could be endogenous ligands modulating the serotonin transporter and potentially contributing to depression.

    Related Experiment Videos